Our objective was to (a) develop a framework to understand and quantify the relationship between anticancer drug exposure, tumor dynamics, and CRP to (b) identify early longitudinal prognostic predictors of the commonly used clinical efficacy endpoints, progression-free survival (PFS), and overall survival (OS), in advanced NSCLC patients treated with first-line platinum-based chemotherapy. This evidence concerns the gene CRP and neoplasm.